Sigyn CardioDialysis™ reduces the circulating presence of cholesterol-transporting proteins and inflammatory molecules associated with Major Adverse Cardiovascular Events (MACE).
Our CompanyThe annual global market for therapies to reduce MACE
Sigyn CardioDialysis™ is designed for use on dialysis machines that help support and extend the lives of individuals with end-stage renal disease at ~7,500 U.S. dialysis clinics.
"We create medical technologies with two attributes in mind: they must offer to overcome a clearly-defined therapeutic limitation and if demonstrated to be effective, would provide a strategic competitive advantage within an established industry."
Jim Joyce
Chairman and CEO Inventor
Stay informed and receive company updates straight to your inbox.
